Patient Characteristics and Outcomes Measured
We conducted a retrospective analysis of HCT patients treated at Mattel Children’s Hospital at the University of California, Los Angeles. This study was approved by the UCLA institutional review board (IRB # 17-001107). All patients who received HCT over a 14-year period between 2005 and 2018 were included in this study.
Data on diagnosis, age at transplant, sex, ethnicity, malignant, relationship to donor, stem cell source, antigen mismatch, and conditioning regimen with total body irradiation (TBI) were collected. Post-transplant follow-up data included acute graft vs. host disease (GVHD) within the first 100 days, chronic GVHD after 100 days and use of steroids, rates of viral infection, time to platelet and neutrophil engraftment, and overall survival.